Every 424B that Apogee Therapeutics Inc (APGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow APGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APGE filings page.
Apogee Therapeutics, Inc. is conducting a registered public offering of 5,000,000 shares of its voting common stock at a public offering price of $70.00 per share. The offering is expected to deliver approximately $329.0 million in proceeds to Apogee, before expenses, and the underwriters have a 30-day option to purchase up to an additional 750,000 shares.
The company estimates pro forma net tangible book value per share of $16.64 after this offering, implying immediate dilution of $53.36 per share to new investors. Apogee intends to use net proceeds to fund preclinical studies, clinical trials, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes, and estimates the combined cash resources will fund operations into the first quarter of 2029 under current plans.
Apogee Therapeutics, Inc. is offering $300,000,000 of its voting common stock in a registered underwritten offering, with the underwriters holding a 30-day option to purchase an additional $45,000,000 of shares.
The prospectus supplement states proceeds will be received by the issuer and that net proceeds are intended to fund preclinical studies, clinical trials, manufacturing, commercial readiness, research and development, capital expenditures, working capital and general corporate purposes. Shares outstanding were 69,038,943 as of December 31, 2025.
Apogee Therapeutics, Inc. is offering 6,951,221 shares of voting common stock and, in lieu of shares to certain investors, 365,853 pre-funded warrants at a public offering price of $41.00 per share (pre-funded warrants priced at $40.99999). The company estimates net proceeds of approximately $281.0M, or about $323.3M if the underwriters fully exercise a 30-day option to purchase an additional 1,097,561 shares. Proceeds are intended to fund preclinical and clinical development, manufacturing, commercial readiness and general corporate purposes, and together with existing cash are expected to fund operations into the first half of 2028. Recent clinical updates include an increased Part B enrollment target of 320 patients for the APEX Phase 2 APG777 atopic dermatitis trial, with Part A topline maintenance data expected in Q1 2026 and Part B 16-week induction topline data expected in Q2 2026, and Phase 1b asthma topline data expected in Q1 2026. The pre-funded warrants will not be listed and have limited liquidity; holders have no stockholder rights until exercise.
Apogee Therapeutics, Inc. is offering shares of its voting common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.00001 per share. The company’s common stock trades on Nasdaq under the symbol APGE and had a last reported sale price of $39.73 on October 7, 2025. Apogee is a clinical-stage biotech focused on antibody programs for inflammatory and immunology indications, including atopic dermatitis and asthma.
Recent updates increase the planned Part B enrollment in the APEX Phase 2 trial of APG777 to 320 patients, with Part A maintenance topline data expected in Q1 2026, Part B 16-week induction topline in Q2 2026, and Phase 1b asthma topline in Q1 2026. The prospectus discloses pro forma historical net tangible book value of $619.4M ($10.39 per share as of June 30, 2025) and warns of dilution, limited liquidity for pre-funded warrants, and the need for additional capital to reach regulatory approval and commercialization.